AK109 + paclitaxel

AK109 + paclitaxel is an investigational combination regimen under study for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma, particularly in patients who have progressed after first-line immunochemotherapy. AK109 (also known as pulocimab) is a humanized monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting tumor angiogenesis. Paclitaxel is a well-established antineoplastic agent that stabilizes microtubules, leading to cell cycle arrest and apoptosis. The combination aims to leverage antiangiogenic effects with direct cytotoxicity for enhanced efficacy in difficult-to-treat cancers. AK109 is developed by Akeso Biopharma. This combination, often studied alongside immunotherapies such as cadonilimab (AK104), is currently in Phase 3 clinical trials for gastric cancer, with earlier studies suggesting manageable safety and promising preliminary antitumor activity[1][2][3].

Other names

pulocimab + paclitaxel